- Home
- FMC vs PRAX Comparison
FMC vs PRAX Comparison
Compare FMC & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMC
- PRAX
- Stock Information
- Founded
- FMC 1910
- PRAX 2015
- Country
- FMC United States
- PRAX United States
- Employees
- FMC N/A
- PRAX N/A
- Industry
- FMC Major Chemicals
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- FMC Industrials
- PRAX Health Care
- Exchange
- FMC Nasdaq
- PRAX Nasdaq
- Market Cap
- FMC 4.6B
- PRAX 4.0B
- IPO Year
- FMC N/A
- PRAX 2020
- Fundamental
- Price
- FMC $13.90
- PRAX $190.41
- Analyst Decision
- FMC Buy
- PRAX Strong Buy
- Analyst Count
- FMC 12
- PRAX 12
- Target Price
- FMC $26.91
- PRAX $212.42
- AVG Volume (30 Days)
- FMC 7.6M
- PRAX 814.9K
- Earning Date
- FMC 10-29-2025
- PRAX 11-05-2025
- Dividend Yield
- FMC 16.69%
- PRAX N/A
- EPS Growth
- FMC N/A
- PRAX N/A
- EPS
- FMC N/A
- PRAX N/A
- Revenue
- FMC $3,608,400,000.00
- PRAX $7,463,000.00
- Revenue This Year
- FMC N/A
- PRAX N/A
- Revenue Next Year
- FMC $3.27
- PRAX $44.43
- P/E Ratio
- FMC N/A
- PRAX N/A
- Revenue Growth
- FMC N/A
- PRAX 364.98
- 52 Week Low
- FMC $12.87
- PRAX $26.70
- 52 Week High
- FMC $61.26
- PRAX $206.71
- Technical
- Relative Strength Index (RSI)
- FMC 17.02
- PRAX 65.01
- Support Level
- FMC $12.87
- PRAX $159.74
- Resistance Level
- FMC $14.31
- PRAX $188.53
- Average True Range (ATR)
- FMC 1.13
- PRAX 14.09
- MACD
- FMC -0.17
- PRAX -4.40
- Stochastic Oscillator
- FMC 5.64
- PRAX 66.19
About FMC FMC Corporation
FMC is a pure-play global crop protection company with a fairly balanced product portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop protection companies and focuses on the development of new products, including biologicals, through its research and development pipeline.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.